PharmaLundensis is a research company. Main focus is on the treatment of severe pulmonary diseases. The three diseases the company is specialised in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition, development is made on system that eliminates the release of pharmaceutical pollution. PharmaLundensis is based in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Staffan Skogvall | 51,56 | 51,56 | 2025-03-27 |
| Vict Th Engwalls Stiftelse | 2,75 | 2,75 | 2025-03-27 |
| Arne Skogvall | 2,09 | 2,09 | 2025-03-27 |
| Arne Arvidsson | 1,88 | 1,88 | 2025-03-27 |
| Avanza Pension | 1,14 | 1,14 | 2025-03-27 |
| Nordnet Pensionsförsäkring | 0,70 | 0,70 | 2025-03-27 |
| Tommy Johansson | 0,66 | 0,66 | 2025-03-27 |
| Staffan Engelbert Bodén | 0,57 | 0,57 | 2025-03-27 |
| Merrick Lee Tabor | 0,42 | 0,42 | 2025-03-27 |
| Monica Billgert | 0,42 | 0,42 | 2025-03-27 |
2025-07-15 Årsstämma 2024
2025-08-21 Delårsrapport 2025-Q2
2025-11-20 Delårsrapport 2025-Q3
2026-02-19 Bokslutskommuniké 2025